<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02962102</url>
  </required_header>
  <id_info>
    <org_study_id>2016P002527</org_study_id>
    <secondary_id>5K23DK106448</secondary_id>
    <nct_id>NCT02962102</nct_id>
  </id_info>
  <brief_title>Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury</brief_title>
  <acronym>ACTIVATE-AKI</acronym>
  <official_title>Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury (ACTIVATE-AKI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Leaf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of calcifediol (25-hydroxyvitamin D) and
      calcitriol (1,25-dihydroxyvitamin D) in preventing and reducing the severity of acute kidney
      injury (AKI) in critically ill patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kidney Injury</measure>
    <time_frame>7 days</time_frame>
    <description>Composite of daily serum creatinine, need for renal replacement therapy (RRT), or death within 7 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New or worsening stage of AKI, defined by KDIGO guidelines</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak serum creatinine (mg/dl)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary injury markers (neutrophil gelatinase-associated lipocalin [NGAL], interleukin 18 [IL-18], and kidney injury molecule-1 [KIM-1])</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ-failure free days</measure>
    <time_frame>7 days</time_frame>
    <description>Assessed by daily Sequential Organ Failure Assessment (SOFA) scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypercalcemia, defined as serum total calcium &gt; 10.7 mg/dl</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU- and hospital-free days</measure>
    <time_frame>28 days</time_frame>
    <description>28 minus the number of days in the ICU or hospital, with 0 assigned to patients who die before 28 days</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Kidney Injury - Subgroup analysis based on time zero 25-hydroxyvitamin D level above versus below the median</measure>
    <time_frame>7 days</time_frame>
    <description>Composite of daily serum creatinine, need for renal replacement therapy (RRT), or death within 7 days</description>
  </other_outcome>
  <other_outcome>
    <measure>Kidney Injury - Subgroup analysis based on the presence or absence of AKI on enrollment</measure>
    <time_frame>7 days</time_frame>
    <description>Composite of daily serum creatinine, need for renal replacement therapy (RRT), or death within 7 days</description>
  </other_outcome>
  <other_outcome>
    <measure>Kidney Injury - Subgroup analysis based on APACHE II score on enrollment above versus below the median</measure>
    <time_frame>7 days</time_frame>
    <description>Composite of daily serum creatinine, need for renal replacement therapy (RRT), or death within 7 days</description>
  </other_outcome>
  <other_outcome>
    <measure>Kidney Injury - Subgroup analysis based on ICU type (medical versus surgical)</measure>
    <time_frame>7 days</time_frame>
    <description>Composite of daily serum creatinine, need for renal replacement therapy (RRT), or death within 7 days</description>
  </other_outcome>
  <other_outcome>
    <measure>Kidney Injury - Subgroup analysis based on the presence or absence of sepsis on enrollment</measure>
    <time_frame>7 days</time_frame>
    <description>Composite of daily serum creatinine, need for renal replacement therapy (RRT), or death within 7 days</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Critically Ill</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Calcifediol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcifediol 400mcg PO/NGT/OGT x 1, followed by 200mcg PO/NGT/OGT daily x 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcitriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcitriol 4mcg PO/NGT/OGT daily x 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Equal volume of medium chain triglyceride (MCT) oil daily x 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcifediol</intervention_name>
    <description>Calcifediol 400mcg PO/NGT/OGT x 1, followed by 200mcg PO/NGT/OGT daily x 4</description>
    <arm_group_label>Calcifediol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <description>Calcitriol 4mcg PO/NGT/OGT daily x 5</description>
    <arm_group_label>Calcitriol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo (medium chain triglyceride oil) daily x 5</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18

          -  Admitted to the ICU within 48h prior to enrollment

          -  Likely to remain in the ICU (alive) for ≥72h

          -  Naso/orogastric tube or ability to swallow

          -  High risk of severe AKI

        Exclusion Criteria:

          -  Serum total calcium &gt; 9.0 mg/dl or phosphate &gt; 6.0 mg/dL within previous 48h

          -  Currently receiving oral calcium supplementation

          -  Ingestion of vitamin D3 &gt;1,000 IU/day or any 25-hydroxyvitamin D or
             1,25-dihydroxyvitamin D during the previous 7 days

          -  AKI stage 2 or 3 (based on KDIGO serum creatinine and/or urine output criteria)

          -  History of transplantation or receiving chronic (&gt;7days) of immunosuppressive
             medications (not including glucocorticoid steroids at a dose less than or equivalent
             to prednisone 20 mg/day)

          -  Neutropenia in the previous 48h

          -  Active primary parathyroid disease, active granulomatous disease, or symptomatic
             nephrolithiasis in the previous 3 months

          -  Receiving cytochrome P450 inhibitors

          -  Chronic Kidney Disease stage V or End Stage Renal Disease

          -  Hemoglobin &lt; 7 g/dL

          -  GI malabsorption

          -  Prisoner

          -  Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David E Leaf, MD, MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David E Leaf, MD, MMSc</last_name>
    <phone>617-732-5500</phone>
    <email>deleaf@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David E. Leaf, M.D.</last_name>
      <phone>617-732-5951</phone>
      <email>DELEAF@partners.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>David Leaf</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine, Harvard Medical School</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Calcifediol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

